Combined HCC-MFCCC
Completed
- Conditions
- Liver CarcinomaCholangiocarcinomaSurgeryHepatocellular Carcinoma
- Interventions
- Procedure: Hepatectomy
- Registration Number
- NCT03178409
- Lead Sponsor
- University of Milan
- Brief Summary
Combined hepatocellular and mass-forming cholangiocarcinoma (cHCC-MFCCC) is a rare tumor. The aim of this study was the analysis of the outcome comparing such tumor with classic hepatocellular carcinoma (HCC) and mass-forming cholangiocarcinoma (MFCCC).
- Detailed Description
The institutional prospectively maintained database was queried, and 20 patients with cHCC-MFCCC were identified. A 2:1 match was performed with 40 patients operated in the same period for HCC, and with 40 operated for MFCCC. Only T1 or T2 patients N0 M0 were considered. Primary endpoint was the overall survival (OS) and disease-free survival (DFS).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- positive histology for cHCC-MFCCC, HCC, and MFCCC
- complete clinical, surgical, pathological and follow-up data.
Exclusion Criteria
- patients preoperatively treated with chemotherapy, radiofrequency ablation or trans-arterial therapies were excluded.
- patients operated for recurrent disease and/or with non-radical surgery
- patients with missing data were also excluded
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description cHCC-MFCCC Hepatectomy Patients affected by combined HCC-MFCCC MFCCC Hepatectomy Patients affected by classical MFCCC HCC Hepatectomy Patients affected by classical HCC
- Primary Outcome Measures
Name Time Method Survival analysis From 3 months after surgery up to 60 months after surgery Analysis of overall and disease-free survival of patients resected for cHCC-MFCCC versus those resected for HCC versus those resected for MFCCC
- Secondary Outcome Measures
Name Time Method